Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases.
Kosse LJ, Jessurun NT, Vonkeman HE, Tas SW, Nurmohamed MT, Hoentjen F, van Doorn MBA, van Puijenbroek EP, van den Bemt BJF, de Vries M. Kosse LJ, et al. Among authors: tas sw. Expert Opin Drug Saf. 2020 Nov;19(11):1521-1528. doi: 10.1080/14740338.2020.1803826. Epub 2020 Aug 12. Expert Opin Drug Saf. 2020. PMID: 32730115
Perspective of patients with autoimmune diseases on COVID-19 vaccination.
Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, Nurmohamed MT, Boers M, Kuijpers TW, van Ham SM, Eftimov F, Wieske L, Rispens T, Wolbink GJ. Boekel L, et al. Among authors: tas sw. Lancet Rheumatol. 2021 Apr;3(4):e241-e243. doi: 10.1016/S2665-9913(21)00037-0. Epub 2021 Feb 22. Lancet Rheumatol. 2021. PMID: 33655220 Free PMC article. No abstract available.
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes.
Kosse LJ, Weits G, Vonkeman HE, Tas SW, Hoentjen F, Van Doorn MB, Spuls PI, D'Haens GR, Nurmohamed MT, van Puijenbroek EP, Van Den Bemt BJ, Jessurun NT. Kosse LJ, et al. Among authors: tas sw. Expert Opin Drug Saf. 2021 Dec;20(12):1565-1572. doi: 10.1080/14740338.2021.1963436. Epub 2021 Aug 12. Expert Opin Drug Saf. 2021. PMID: 34348543
Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry".
van Vollenhoven RF, Tas SW, Nurmohamed MT. van Vollenhoven RF, et al. Among authors: tas sw. Ann Rheum Dis. 2023 Aug;82(8):e177. doi: 10.1136/annrheumdis-2021-221146. Epub 2021 Aug 13. Ann Rheum Dis. 2023. PMID: 34389606 Free PMC article. No abstract available.
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, van Dam KPJ, Stalman EW, Vogelzang EH, Cristianawati O, Keijzer S, Vidarsson G, Voskuyl AE, Wieske L, Eftimov F, van Vollenhoven R, Kuijpers TW, van Ham SM, Tas SW, Killestein J, Boers M, Nurmohamed MT, Rispens T, Wolbink G. Boekel L, et al. Among authors: tas sw. Lancet Rheumatol. 2021 Nov;3(11):e778-e788. doi: 10.1016/S2665-9913(21)00222-8. Epub 2021 Aug 6. Lancet Rheumatol. 2021. PMID: 34396154 Free PMC article.
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
van Lint JA, van Hunsel FPAM, Tas SW, Vonkeman HE, Hoentjen F, van Doorn MBA, Hebing RCF, Nurmohamed MT, van den Bemt BJF, van Puijenbroek EP, Jessurun NT. van Lint JA, et al. Among authors: tas sw. Ann Rheum Dis. 2022 Apr;81(4):597-599. doi: 10.1136/annrheumdis-2021-221840. Epub 2021 Dec 16. Ann Rheum Dis. 2022. PMID: 34916208 No abstract available.
157 results